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Background: Apoptosis is an essential property of all higher organisms that involves extremely complex signaling
pathways. Mathematical modeling provides a rigorous integrative approach for analyzing and understanding such
intricate biological systems.
Results: Here, we constructed a large-scale, literature-based model of apoptosis pathways responding to an
external stimulus, cisplatin. Our model includes the key elements of three apoptotic pathways induced by cisplatin:
death receptor-mediated, mitochondrial, and endoplasmic reticulum-stress pathways. We showed that
cisplatin-induced apoptosis had dose- and time-dependent characteristics, and the level of apoptosis was saturated
at higher concentrations of cisplatin. Simulated results demonstrated that the effect of the mitochondrial pathway
on apoptosis was the strongest of the three pathways. The cross-talk effect among pathways accounted for
approximately 25% of the total apoptosis level.
Conclusions: Using this model, we revealed a novel mechanism by which cisplatin induces dose-dependent cell
death. Our finding that the level of apoptosis was affected by not only cisplatin concentration, but also by cross talk
among pathways provides in silico evidence for a functional impact of system-level characteristics of signaling
pathways on apoptosis.
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Cisplatin is an effective chemotherapeutic agent widely
used in the treatment of cancer [1,2], but it has several
side effects, including dose-dependent renal cell death
and nephrotoxicity [3-6]. Uptake of cisplatin occurs
mainly through the organic transporter pathway, and the
kidney accumulates cisplatin to a greater degree than
other organs. These events cause tubular damage and
tubular dysfunction [5]. High concentrations of cisplatin
lead to necrosis in proximal tubule cells, whereas lower
concentrations induce apoptosis [7-10].
Recent studies have indicated that extranuclear events in-
volving mitochondria [11], endoplasmic reticulum (ER)
[12], and lysosomes [13] may be important for the* Correspondence: ebshim@kangwon.ac.kr
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reproduction in any medium, provided the orinduction of cellular apoptosis by cisplatin [12]. Apoptosis
can also be triggered by extracellular death signals,
deprivation of survival signals, and genetic damage [14].
Experimental observations [15-22] have shown that apop-
tosis occurs along three major pathways: i) an extrinsic
pathway mediated by death receptors, ii) an intrinsic path-
way centered on mitochondria, and iii) an ER-stress path-
way (Figure 1A).
Despite numerous experimental studies, the biological
mechanism underlying the apoptotic effect of cisplatin is
not yet completely understood. In particular, because cel-
lular apoptosis is related to complicated and interactive
signaling pathways and also depends on the cisplatin con-
centration [11], an experimental approach alone may not
be cost effective for delineating the complex mechanism
of cisplatin-induced apoptosis. Thus, a theoretical ap-
proach based on mathematical formulations can provide
an alternative to complement experimental methods.
A variety of theoretical studies have investigated the
effects of specific pathways or variables related totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 (See legend on next page.)
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Figure 1 Mathematical model of the apoptotic pathways induced by cisplatin. (A) Schematic description of the apoptotic pathways
induced by cisplatin. (B) Simplified model of apoptotic pathways. Cisplatin activates the three major pathways of apoptosis: i) the extrinsic
pathway mediated by death receptors; ii) the intrinsic pathway centered on mitochondria; iii) the endoplasmic reticulum (ER)-stress pathway.
Solid arrows denote chemical reactions or upregulation; those terminated by a bar denote inhibition or downregulation.
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a mechanistic mathematical model describing key ele-
ments of receptor-mediated and stress-induced caspase
activation. Choi et al. [24] focused on the “slow induc-
tion plus fast switching” mechanism of caspase-3 using a
simplified model. Apoptosis can also occur in responseFigure 2 Simulated results of the variables related to the death recep
into cells, thus activating FasL. Aqcis, aquated cisplatin; FasL*, activated Fas
caspase-8. FasL*_Casp8, binding of FasL* and Casp-8; Casp8*, activated cas
to the activation of downstream caspase-3 and causes apoptosis. Casp8*_c
Interaction between activated caspase-8 and caspase-3 activation (D) or ap
Casp8* × 2.0, activated caspase-8 increase by twofold; Casp8* × 0.2, activato activation of the mitochondrial apoptotic pathway
[25]. Legewie et al. [26] proposed a mathematical model
for the mitochondrial pathway of caspase activation,
which is essential for induction of apoptosis by various
stimuli, including cytotoxic stress. However, most previ-
ous models have focused on partial signaling pathwaystor pathway. (A) Cisplatin becomes aquated and toxic after its entry
L. (B) Activated FasL binds caspase-8 and activates the initiator
pase-8; Casp8, procaspase-8. (C) The activated caspase-8 leads directly
asp3, binding of Casp8* and casp3; Casp3*, activated caspase-3.
optosis (E). Casp8* × 1.0, activated caspase-8 at baseline value;
ted caspase-8 decrease by fivefold.
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ies have examined an integrative model that includes all
three major pathways of apoptotic signaling induced by
cisplatin.
In this study, we constructed a large-scale, literature-
based mathematical model to gain a systematic under-
standing of the biological mechanisms underlying
cisplatin-induced apoptosis. Using the model, sequential
signaling events, from the uptake of cisplatin to cellular
apoptosis, were simulated. We then analyzed the charac-
teristics of dose-dependent cellular apoptosis and cross-
talk effects among the three apoptosis pathways through
extensive simulations.Figure 3 Simulated results of the variables related to the mitochondr
(B) DNA damage activates ATR and p53. ATR*_p53, binding of ATR* and p5
of p53* and casp2, (D) leading to AIF release from mitochondria and subse
AIF, leaked AIF in the cytosol. (E, F) On the other hand, apoptosis induced
cytochrome c release. Cyt.c, leaked cytochrome c in the cytosol; p53*_Bax,Results and discussions
Model structure
A schematic representation of the apoptotic signaling
network described by our computational model is shown
in Figure 1B. The model starts with the uptake of cis-
platin into a cell by organic cation transporter 2
(OCT2). After entering the cell, cisplatin is aquated into
a highly reactive form that can bind to and induce modi-
fication of various molecules [27,28]. Cisplatin activates
the three major pathways of apoptosis: i) the extrinsic
pathway mediated by death receptors, ii) the intrinsic
pathway centered on mitochondria, and iii) the ER stress
pathway [3,4,6,12].ial pathway by DNA damage. (A) Cisplatin induces DNA damage.
3. (C) P53 then induces activation of caspase-2. p53*_Casp2, binding
quent caspase-independent apoptosis. AIFmit, AIF in mitochondria;
by p53 binding with Bax is dependent on Bax/Bak, which induces
binding of p53* and Bax; Bax_Bak, binding of Bax and Bak.
Hong et al. BMC Systems Biology 2012, 6:122 Page 5 of 16
http://www.biomedcentral.com/1752-0509/6/122First, in the extrinsic pathway, binding of the death
receptors by ligands at the plasma membrane leads to
the recruitment and activation of caspase-8, which fur-
ther activates downstream caspases to induce apoptosis,
because the expression levels of FasL, Fas, and tumor
necrosis factor-alpha (TNF-α) increase in response to
cisplatin [29-31]. Second, the mitochondrial pathway is
the major apoptotic pathway involved in the nephrotox-
icity of cisplatin. Cisplatin induces DNA damage, which
activates ataxia telangiectasia and Rad-3-related (ATR),
resulting in the phosphorylation and activation of p53.
Then, p53 activates caspase-2 to elicit apoptosis-
inducing factor (AIF) release from mitochondria and
subsequent caspase-independent apoptosis. The capacityFigure 4 Simulated results of the variables related to the mitochondr
by cisplatin induces MPTP. Aqcis, aquated cisplatin; mitROS, increased ROS
transition pore. (B) MPTP induces cytochrome c release, which activates ca
mitochondria; Cyt.c_Casp9, binding of Cyt.c and Casp9. (C, D) IAP inhibits a
binding of Casp9* and IAP; Casp3*_IAP, binding of Casp3* and IAP; Casp9*
subsequently initiates caspase-3 activation (D) and induces apoptosis (E).of p53 to directly activate Bax to permeabilize mitochon-
dria permits an uninterrupted pathway leading, e.g.,
from DNA damage to the mitochondrial release of cyto-
chrome c, caspase activation, and apoptosis [3,32-34]. In
addition, cisplatin induces mitochondrial dysfunction
and increases reactive oxygen species (ROS) production
via the disrupted respiratory chain [35]. Oxidative injury
of mitochondrial function and mtDNA (mitochondrial
DNA) in the kidney are early events elicited by cisplatin
[36]. Uncontrollable production of ROS triggers opening
of mitochondrial permeability transition pores (MPTP)
and induces apoptosis through the release of cytochrome
c from mitochondria into the cytosol [37-40]. Third, in
the ER stress pathway, increased cytosolic calcium andial pathway by oxidative stress. (A) Increased ROS in mitochondria
in mitochondria; mitPTP*, opened mitochondrial permeability
spase-9. Cyt.c, cytochrome c in cytosol; Cyt.cmit, cytochrome c in
ctivated caspase-9 and −3, which induce apoptosis. Casp9*_IAP,
_Casp3, binding of Casp9* and Casp3. Activated caspase-9
Figure 5 Interaction between apoptosis and AIF, p53 activation, IAP, Bcl-2, or Cyt.c. (A) Interaction between apoptosis and p53* or IAP.
Inhibition of p53 and AIF shows a decrease in apoptosis. × 1.0, baseline value; p53* × 0.3, activated p53 decrease by thirtyfold; AIF × 0.1, AIF
decrease by tenfold. (B) Interaction between Casp3* and IAP without IAP, IAP = 0; with IAP, IAP at baseline value; IAP × 0.2, IAP decrease by
twentyfold. (C) Interaction between apoptosis and IAP. Bcl-2 impairs activation of Bax/Bak. (D) Interaction between Bax_Bak and Bcl-2. Bcl-2 × 1.0,
Bcl-2 at baseline value; Bcl-2 × 0.1, Bcl-2 decrease by tenfold; Bcl-2 × 10.0, Bcl-2 increase by tenfold. (E) Interaction between apoptosis and Cyt.c.
with Cyt.c, Cyt.c at baseline value; Cyt.c × 5.0, Cyt.c increase by fivefold; Cyt.c × 0.2, Cyt.c decrease by fivefold. (F) Interaction between apoptosis
and Bcl-2 without Bcl-2, Bcl-2 = 0; with Bcl-2, Bcl-2 at baseline value; Bcl-2 × 0.2, IAP decrease by twentyfold.
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http://www.biomedcentral.com/1752-0509/6/122calpain activation are early events in cisplatin-induced
apoptosis [41]. Calpain is a protease responsible for acti-
vation of caspase-12 [42], which is localized at the cyto-
solic face of the ER [43]. Cisplatin induces apoptosis in
the absence of DNA damage, and the ER is likely its
nonnuclear target [12].Baseline results of cisplatin-induced apoptosis
Figure 2 presents time series of the equation variables
related to the death receptor pathway. The proteins of
the TNF-α receptor family, including Fas ligand (FasL)
and TNF receptor 1 (TNFR 1), play important roles in
apoptotic cell death. FasL activates the initiator caspase-Figure 6 Simulated results of the variables related to the ER-stress pa
from the ER. Ca2+ was leaked from the ER. Ca2+ activates calpain (B), which
binding of Ca2+ and Calpain; Calpain*_Casp12, binding of Calpain* and Cas
binding of Casp12* and Casp9. (E) Activated caspase-9 and −3 cause apop
The simulation is based on a model with (× 1.0) or without activated caspa8 (Figure 2A, B), and then activated caspase-8 leads dir-
ectly to the activation of downstream caspase-3, causing
apoptosis (Figure 2C) [29]. Similar to previous experi-
ments of cisplatin-induced cell death [44,45]; all variable
curves were plotted until 24 h after uptake of cisplatin.
To evaluate the interaction between activated caspase-8
and caspase-3 activation or apoptosis, we tested our
mathematical model for different levels of activated
caspase-8 expression. Less-activated caspase-8 implies
reduced caspase-3 activation and apoptosis (Figure 2D,
E). Activated caspase-8 initiates a caspase cascade by
processing the effectors caspase-3, -6, and −7, which in
turn cleave many protein substrates. These results
showed similar patterns to those reported in thethway. (A) Cisplatin induces ER stress and leads to release of Ca2+
cleaves procaspase-12 to mature caspase-12 (C). Ca2+_Calpain,
p12. (D) Activated caspase-12 initiates caspase-9. Casp12*_Casp9,
tosis. (F) Interaction between apoptosis and activated caspase-12.
se-12. Casp12* × 0.05, Casp12* decrease by twofold.
Figure 7 Effect of cisplatin concentration on caspase activity and apoptosis. (A, B) Relationship between apoptosis and various
concentrations of cisplatin. Cisplatin induces dose-dependent apoptosis. C, D, and E show the activation of caspase-8, -3, and −9, respectively,
with increasing doses of cisplatin for 24 h. (F) Effect of apoptosis by each pathway.
Table 1 Apoptotic variation in response to cisplatin
concentration and pathway








(A) Apoptosis level in various concentrations of cisplatin. (B) Apoptosis level in
each pathway.
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ator caspase in death receptor signaling.
Time-dependent curves of the variables related to
the mitochondrial pathway of apoptosis due to mtDNA
damage and oxidative stress are plotted in Figures 3Table 2 Apoptosis level in each pathway
Pathway Apoptosis level
Total 0.22512 (100%)
Pathway I 0.065424 (29.1%)
Pathway II 0.103267 (45.9%)
Pathway III 1.83E-4 (0.08%)
Cross talk effect 0.0561 (24.9%)
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k+, forward rate constant of reaction; k–, reverse rate constant of reaction; Casp12*, activated caspase-12.
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http://www.biomedcentral.com/1752-0509/6/122and 4, respectively. The p53 activated by DNA damage
activates caspase-2 to induce AIF (Figure 3A–D) and
the Bax-mediated mitochondrial pathway (Figure 3E, F)
for apoptosis [46,47]. Cytochrome c is released from mito-
chondria into the cytosol after activation of Bax insertion
into mitochondrial membranes and cytochrome c add-
itionally activates caspase-3 (Figure 3E, F) [48,49]. AIF is
another protein released from mitochondria into thecytosol that causes apoptosis in a caspase-independent
manner by inducing DNA damage in the nucleus
(Figure 3D) [50,51]. Cisplatin also induces ROS production
via the disrupted respiratory chain [35]. Overproduction of
ROS in mitochondria induces MPTP opening, and cyto-
chrome c is released from mitochondria through MPTP in
the early stages of apoptosis (Figure 4A, B) [37]. Cytosolic
cytochrome c (Figure 4B) activates caspase-9 (Figure 4C),
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http://www.biomedcentral.com/1752-0509/6/122which triggers caspase-3 (Figure 4D) and causes conse-
quent apoptosis (Figure 4E).
When we inhibited p53 or AIF, the simulated graphs
showed similar patterns to previously reported experimen-
tal results [32]: inhibition of p53 or AIF provides protec-
tion against cisplatin-induced apoptosis (Figure 5A).
Reduced inhibitor of apoptosis protein (IAP) increases the
concentration of activated caspase-3, increasing the prob-
ability of apoptosis (Figure 5B, C). The anti-apoptotic pro-
tein Bcl-2 impairs the activation of Bax/Bak (Figure 5D),
thereby maintaining mitochondrial membrane integrity
and reducing cytochrome c leakage, which results in a de-
crease in the probability of apoptosis (Figure 5E). How-
ever, a reduction in Bcl-2 expression slightly increases the
probability of apoptosis (Figure 5F).
Accumulation of excessive proteins or disruption of cal-
cium homeostasis in the ER can cause apoptosis due to ER
stress [42,52]. Transient curves of the variables related to
the ER-stress pathway are presented in Figure 6. ER stress
causes conformational changes and/or oligomerization of
pro-apoptotic Bak and Bax at the ER membrane [53],Table 4 Ordinary differential equation
Ordinary differential equations
d Aqcis½ =dt ¼ kþ1 Cis½  OCT2½ 
d Ca2þ½ =dt ¼ kþ2 Aqcis½  ER½   kþ3 Ca2þ½  Calpain½  þ k3 Ca2þ⋅Calpain½ 
d Calpain½ =dt ¼ kþ3 Ca2þ½  Calpain½  þ k3 Ca2þ⋅Calpain½ 
d Ca2þ⋅Calpain½ =dt ¼ kþ3 Ca2þ½  Calpain½  þ k3 Ca2þ⋅Calpain½ kþ4 Ca2þ⋅Calpain½ 
d Calpain½ =dt ¼ kþ4 Ca2þ⋅Calpain½   kþ5 Calpain½  Casp12½ þk5 Calpain⋅Casp12½ 
d Casp12½ =dt ¼ kþ5 Calpain½  Casp12½  þ k5 Calpain⋅Casp12½ 
d Calpain⋅Casp12½ =dt ¼ kþ5 Calpain½  Casp12½ k5 Calpain⋅Casp12½   kþ6 Calpain⋅Casp12½ 
d Casp12½ =dt ¼ kþ6 Calpain⋅Casp12½   kþ7 Casp12½  Casp9½ þk7 Casp12⋅Casp9½ 
d Casp9½ =dt ¼ kþ7 Casp12½  Casp9½  þ k7 Casp12⋅Casp9½ kþ27 Cytc½  Casp9½  þ k27 Cytc⋅Casp9½ 
d Casp12⋅Casp9½ =dt ¼ kþ7 Casp12½  Casp9½   k7 Casp12⋅Casp9½ kþ8 Casp12⋅Casp9½ 












d Casp3½ =dt ¼ kþ10 Casp9⋅Casp3½  þ kþ36 Casp8⋅Casp3½ kþ13 Casp3½  IAP½  þ k13 Casp3⋅IAP½ 
d IAP½ =dt ¼ kþ12 Casp9½  IAP½  þ k12 Casp9⋅IAP½ kþ13 Casp3½  IAP½  þ k13 Casp3⋅IAP½ 
d Casp9⋅IAP½ =dt ¼ kþ12 Casp9½  IAP½   k12 Casp9⋅IAP½ 
d Casp3⋅IAP½ =dt ¼ kþ13 Casp3½  IAP½   k13 Casp3⋅IAP½ 
d DNAdamage
 






















þleading to release of Ca2+ from the ER (Figure 6A). Ca2+
then activates calpain in the cytosol, which cleaves
procaspase-12 to mature caspase-12 in the ER (Figure 6B,
C) [54]. Activated caspase-12 then initiates a caspase cas-
cade through cleavage of procaspase-9 and thus causes
apoptosis (Figure 6D, E) [55]. Inhibition of caspase-12 acti-
vated by cisplatin induces a slight decrease in the probabil-
ity of apoptosis (Figure 6F). These results suggest that ER
stress and consequent activation of caspase-12 play a role
in cisplatin-induced nephrotoxicity, but their effect on
apoptosis was not remarkable.
Simulation of dose-dependent cell death caused by
cisplatin
Cisplatin has been shown to induce time- and dose-
dependent cell death [56,57]. Although the maximum
concentration of cisplatin was set to 1 in our model, we
simulated the apoptosis level in response to various con-
centrations of cisplatin on a timescale. The increase in
the level of apoptosis was dependent on the concentra-
tion of cisplatin (Figure 7A, B, Table 1). Cisplatin-TR=dt ¼ kþ15 DNAdamage
 
ATR½   kþ16 ATR½  P53½  þ k16 ATR⋅P53½ 
53=dt ¼ kþ16 ATR½  P53½  þ k16 ATR⋅P53½ 
TR⋅P53=dt ¼ kþ16 ATR½  P53½   k16 ATR⋅P53½   kþ17 ATR⋅P53½ 
53=dt ¼ kþ17 ATR⋅P53½  þ k18 P53⋅Casp2½   kþ18 P53½  Casp2½ 
kþ22 P53
½  Bax½  þ k22 P53⋅Bax½   k25 P53½  Bcl2½  þ k25 P53⋅Bcl2½ 
asp2=dt ¼ kþ18 P53½  Casp2½  þ k18 P53⋅Casp2½ 
53⋅Casp2=dt ¼ kþ18 P53½  Casp2½   k18 P53⋅Casp2½   k18 P53⋅Casp2½ 
asp2=dt ¼ kþ19 P53½  Casp2½   kþ20 Casp2½  AIFmit½ 
IFmit =dt ¼ kþ20 Casp2½  AIFmit½ 
IF=dt ¼ kþ20 Casp2½  AIFmit½ 
ax=dt ¼ kþ22 P53½  Bax½  þ k22 P53⋅Bax½ 
53⋅Bax=dt ¼ kþ22 P53½  Bax½   k22 P53⋅Bax½   k23 P53⋅Bax½ 
ax⋅Bak=dt ¼ kþ23 P53⋅Bax½ 
cl2=dt ¼ kþ25 P53½  Bcl2½  þ k25 P53⋅Bcl2½ 
kþ24 Bcl2½  Bax½  þ k24 Bcl2⋅Bax½ 
53⋅Bcl2=dt ¼ kþ25 P53½  Bcl2½   k25 P53⋅Bcl2½ 
cl2⋅Bax=dt ¼ kþ24 Bcl2½  Bax½   k24 Bcl2⋅Bax½ 
itRos=dt ¼ kþ29 Aqcis½  Mit½ 
itPTP=dt ¼ kþ30 mitRos½  mitPTP½ 
ytcmit=dt ¼ kþ26 Bax⋅Bak½  Cytcmit½   kþ31 mitPTP½  Cytcmit½ 
yct=dt ¼ kþ26 Bax⋅Bak½  Cytcmit½   kþ27 Cytc½  Casp9½ 
k27 Cytc⋅Casp9½  þ kþ31 mitPTP½  Cytcmit½ 
ytc⋅Casp9=dt ¼ kþ27 Cytc½  Casp9½   k27 Cytc⋅Casp9½ 
kþ28 Cytc⋅Casp9½ 
asL=dt ¼ kþ32 Aqcis½  FasL½   kþ33 FasL½  Casp8½  þ k33 FasL⋅Casp8½ 
asp8=dt ¼ kþ33 FasL½  Casp8½  þ k33 FasL⋅Casp8½ 
kþ34 FasL
⋅Casp8½ 
asL⋅Casp8=dt ¼ kþ33 FasL½  Casp8½   k33 FasL⋅Casp8½   kþ34 FasL⋅Casp8½
asp8=dt ¼ kþ34 FasL⋅Casp8½   kþ35 Casp8½  Casp3½  þ k35 Casp8⋅Casp3½ 
asp8⋅Casp3dt ¼ kþ35 Casp8½  Casp3½   k35 Casp8⋅Casp3½ 
kþ36 Casp8
⋅Casp3½ 
pop=dt ¼ kþ11 Casp9½  Casp3½  þ kþ21 Casp2½  AIF½ 
kþ37 Casp8
½  Casp3½ 
Table 6 All values are in arbitrary units
Initial conditions
OCT2 1 Apoptosis 0
ER 1 Aqcis 0
Calpain 1 Calpain* 0
Caspase-12 1 Caspase-12* 0
Caspase-9 1 Caspase-9* 0
Caspase-3 1 Caspase-3* 0
IAP 1 Caspase-9*•IAP 0
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http://www.biomedcentral.com/1752-0509/6/122induced apoptosis was further confirmed by the activ-
ities of caspase-9, -8, and −3 (Figure 2C, E and
Figure 6E). Figure 7C–E indicates that increasing doses
of cisplatin can cause significant activation of caspase-8, -3,
and −9. Although the level of apoptosis increased linearly
at lower concentrations of cisplatin, it exhibited a nearly
saturated curve at higher concentrations (Figure 7B). A
previous experimental study [55] also observed a saturated
probability of apoptosis beyond a threshold concentration
of cisplatin.DNA 1 DNA damage 0
ATR 1 ATR* 0
p53 1 p53* 0
AIFmit 1 AIF 0
Bax 1 Bax•Bak 0
Bcl-2 1 p53*•Bcl-2 0
Mit 1 Cyt.c•Caspase-9 0
mitPTP 1 mitPTP* 0
Cyt.cmit 1 Cyt.c 0
Caspase-8 1 Caspase-8* 0
FasL 1 FasL* 0
Caspase-2 1 Caspase-2* 0
Ca2+ 0 Caspase-8*•Caspase-3 0
Ca2+•Calpain 0 FasL*•Caspase-8 0Analysis of cross-talk effects of apoptotic signaling
pathways
To evaluate the relative contribution of each signaling
pathway to apoptosis, we first simulated three test cases
in which only one pathway among the three was acti-
vated, with the other two pathways fully inactivated
(Figure 7F, Table 2). According to the results, the mito-
chondrial pathway made the greatest contribution to the
level of apoptosis (46%), whereas the contribution of the
ER stress pathway (0.08%) was negligible. The contribu-
tion of the death-receptor pathway was about 29%. The
sum of the contributions of the three pathways was about
75% and lower than that of the whole model including all
three pathways (Table 2). Thus, we hypothesize that cross
talk among pathways accounts for 25% of theTable 5 Parameter values adopted in the model
Reaction rate constants
k1
+ 1 μM-1 s-1 k20
+ 1 μM-1 s-1
k2
+ 0.5 μM-1 s-1 k21+ 1 μM-1 s-1
k3
+ 1 μM-1 s-1 k3- 1 s-1 k22+ 1 μM-1 s-1 k22- 1 s-1
k4
+ 1 s-1 k23
+ 1 s-1
k5
+ 1 μM-1 s-1 k5- 1 s-1 k24+ 1 μM-1 s-1 k24- 1 s-1
k6
+ 1 s-1 k25
+ 1 μM-1 s-1 k25- 1 s-1
k7
+ 10 μM-1 s-1 k7- 0.5 s-1 k26+† 10 μM-1 s-1
k8
+ 1 s-1 k27
+ 1 μM-1 s-1 k27- 1 s-1
k9
+† 10 μM-1 s-1 K9-† 0.5 s-1 k28+ 1 s-1
k10
+† 0.1 s-1 k29
+ 0.5 μM-1 s-1
k11
+ 1 μM-1 s-1 k30+ 0.5 μM-1 s-1
k12
+† 5 μM-1 s-1 K12-† 0.0035 s-1 k31+ 1 μM-1 s-1
k13
+† 5 μM-1 s-1 K13-† 0.0035 s-1 k32+ 0.5 μM-1 s-1
k14
+ 0.5 μM-1 s-1 k33+ 1 μM-1 s-1 k33- 1 s-1
k15
+ 0.5 μM-1 s-1 k34+ 1 s-1
k16
+ 1 μM-1 s-1 k16
- 1 s-1 k35
+ 1 μM-1 s-1 k35
- 1 s-1
k17
+ 1 s-1 k36
+ 1 s-1
k18
+ 1 μM-1 s-1 k18
- 1 s-1 k37
+ 1 μM-1 s-1
k19
+ 1 s-1
†, cited parameters [44]. Unit of reaction rate constant: M–1 s–1 for bimolecular
reactions, s–1 for monomolecular reactions [44].
Calpain*•Caspase-12 0 ATR*•p53 0
mitRos 0 Caspase-3*•IAP 0
Caspase-12*•Caspase-9 0 Caspase-9*•Caspase-3 0
p53*•Caspase-2 0 p53*•Bax 0
Bcl-2•Bax 0
*, activated components.contribution to the level of apoptosis. This cross-talk
portion includes the effects of three possible interactions:
i) between death receptor and ER-stress pathways, ii) be-
tween death receptor and mitochondrial pathways, and
iii) between ER-stress and mitochondrial pathways.
Despite substantial progress in understanding the bio-
logical mechanisms of cisplatin-induced apoptosis, several
questions remain. In particular, complicated molecular
interactions, such as cross talk among apoptotic pathways,
are not fully understood. In this study, we provided a
mechanism-based mathematical model to gain a compre-
hensive system-level understanding of apoptosis induced
by cisplatin. Because our model simulation can be cost-
effectively repeated for many different sets of conditions,
it provides a useful method for examining complex system
behavior and for guiding experimental design.
Although many mathematical models have analyzed
apoptosis, they have been limited to partial signaling path-
ways or to proteins related to apoptosis. No theoretical
studies have proposed an integrative model that includes
Figure 8 (See legend on next page.)
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Figure 8 Sensitivity analyses of rate constants and initial conditions for the entire model. (A) Sensitivity of each rate constant for
apoptosis. (B) Sensitivity of each initial condition for apoptosis. (C) Sensitivity of each rate constant for whole components.
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cisplatin. Therefore, we aimed to systematically analyze se-
quential molecular events of the apoptotic signaling
process, from the uptake of cisplatin to cross-talk effects
among pathways and ultimately to apoptosis.
We first conducted baseline simulations of cisplatin-
induced apoptosis and compared the results to previous
studies. Our simulations reproduced similar patterns to ex-
perimental data and available information from the litera-
ture (Figure 2A–C, Figure 3, Figure 4, and Figure 6A–E).
We then conducted parametric studies to delineate the
effects of critical signaling molecules on apoptosis. To
evaluate the role of caspase-8 as a major initiator of death
receptor signaling, we simulated variation in activated
caspase-3 and the level of apoptosis based on the level of
activated capase-8 (Figure 2D, E), demonstrating a remark-
able increase in the level of apoptosis at higher concentra-
tions of activated capase-8. In the mitochondrial pathway of
apoptosis, inhibition of p53 or the level of AIF decreased
apoptosis (Figure 5A).
We also showed that cisplatin induces dose-dependent
characteristics of apoptosis (Figure 7A, B, Table 1), but
the apoptosis level was saturated at higher concentra-
tions of cisplatin, similar to a previous experiment [57].
Apoptosis with respect to cisplatin concentration was
also affected by cross talk among pathways (Figure 5 and
Figure 7). To evaluate the contribution of each pathway
to apoptosis, we used a simulation protocol in which
only one pathway was activated while the other two









+ = 1 μM-1 s-1 k1+ = 1.3 0.24
k13
+ = 5 μM-1 s-1 k13+ = 6.5 0.19
k14
+ = 0.5 μM-1 s-1 k14+ = 0.65 0.23
k15
+ = 0.5 μM-1 s-1 k15+ = 0.65 0.23
k29
+ = 0.5 μM-1 s-1 k29+ = 0.65 0.22
k30
+ = 0.5 μM-1 s-1 k30+ = 0.65 0.22
k31
+ = 1 μM-1 s-1 k31+ = 1.3 0.22
k32
+ = 0.5 μM-1 s-1 k32+ = 0.65 0.23
k33
+ = 1 μM-1 s-1 k33
+ = 1.3 0
k34
+ = 1 s-1 k34
+ = 1.3 0.2
k36
+ = 1 s-1 k36
+ = 1.3 0effect of the mitochondrial signaling pathway on apoptosis
was largest (46%), whereas the effect of the ER-stress path-
way was negligible (0.08%). The contribution of the death-
receptor pathway was about 29%. Using mitochondrial
DNA-depleted p0 cells, Hara et al. [58] demonstrated that
mitochondria play a critical role in apoptosis induced by
cisplatin and that mitochondrial DNA is a potential target
for cisplatin. Also, mitochondria-enriched renal cells in
the proximal tubule are critical sites for the occurrence of
side effects of cisplatin [59,60]. These experimental results
suggest that the mitochondrial pathway is the major apop-
totic pathway involved in the nephrotoxicity of cisplatin.
The sum of the contributions of all three pathways to
the total apoptosis level was about 75%, whereas 25% of
the total apoptosis level was attributable to cross talk
among pathways. These results indicated that the level of
apoptosis was affected not only by cisplatin concentration,
but also by cross talk, i.e., complex interactions of molecu-
lar components among pathways.
Conclusions
Although we applied a systematic analysis of the apop-
totic mechanisms induced by cisplatin using a compre-
hensive model, the approach had several limitations.
First, parameter values in the model were based on
values obtained from the literature or adjusted manually
when sufficient information could not be obtained from
the literature or experimental studies. Second, as in pre-
vious studies [61,62], we simply set the initial conditions








+ = 0.7 0.19202 (−14.7%)
674 (−12.6%) k13
+ = 3.5 0.27136 (+20.54%)
067 (+2.46%) k14
+ = 0.35 0.2172 (−3.52%)
067 (+2.46%) k15
+ = 0.35 0.2172 (−3.52%)
952 (+1.95%) k29
+ = 0.35 0.21911 (−2.66%)
952 (+1.95%) k30
+ = 0.35 0.21911 (−2.66%)
952 (+1.95%) k31
+ = 0.7 0.21911 (−2.66%)
424 (+4.05%) k32
+ = 0.35 0.20999 (−6.72%)
.232 (+3.05%) k33
+ = 0.7 0.21389 (−4.98%)
392 (+6.25%) k34
+ = 0.7 0.19967 (−11.3%)
.238 (+5.72%) k36
+ = 0.7 0.20434 (−9.23%)
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meters and initial conditions (described in the “Meth-
ods” section), these limitations were not expected to
greatly alter the main findings of this study. In a future
study, we will design a smaller model that focuses on
the main apoptotic pathway by cisplatin and will obtain
parameters by fitting the model to experimental data.
Methods
Mathematical model
Mathematical descriptions of interactions of the mech-
anistic parts of the pathways were modeled based on
biochemical reaction equations. The signal transduction
network of apoptotic reactions is represented by ordin-
ary differential equations (ODEs). This network leads to
a set of 44 ODEs with 24 reaction partners (Table 3 and
Table 4). In the reactions, the effects of synthesis and
degradation are not taken into account. The differential
equations in the modeling of the signaling pathways
were solved using MATLAB library functions.
Parameters
Simulation of a differential equation requires parameters
for each step of the biochemical reactions. For our model,
parameter values were chosen based on previous experi-
mental reports on various apoptosis pathways [26,63]. For
parameters that had not been reported in the literature,
we adjusted the values to achieve consistency with other
parameters and with output through iterative computa-
tions using MATLAB. Table 5 and Table 6 show kinetic
parameters of the reactions (reaction rate constants) and
the initial conditions of the components. The reaction
rates are dependent on these concentrations and on bio-
chemical parameters. However, most of the kinetic para-
meters and initial concentrations (t = 0) are unknown
and subject to parameter estimation. To resolve the prob-
lem of a large number of unknown parameters, Zhang
et al. [61] and other groups [64-66] used dimensionless
concentrations for all concentrations. Because we do not
have sufficient experimental data and information in the
model, we also used dimensionless concentrations and set
the initial conditions to 0 or 1. The pre-expressed compo-
nents, such as caspase-3 and cytochrome c in mitochon-
dria (Cyt.cmit), were set to 1, and the post-expressed
components by stimulus, such as activated caspase-3 and
leaked cytochrome c in the cytosol (Cyt.cleaked), were set
to 0 at time 0. All values are given in arbitrary units, i.e.,
dimensionless or relative units.
Sensitivity analysis of the model parameters and initial
conditions of the model variables were performed using
SimBiology in MATLAB. As is shown in Figure 8, sensi-
tivity analysis was carried out with respect to rate con-
stants, initial conditions of model variables, and both
rate constants and initial conditions, respectively. Amongthe rate constants, the parameter k1 exhibited a relatively
high sensitivity (Figure 8A). Sensitivity analysis of initial
conditions of the model variables (Figure 8B) showed
that the level of apoptosis was more sensitive to the ini-
tial conditions in terms of Caspase8 and IAP (Figure 8B).
Figure 8C shows the sensitivity of each rate constant for
the whole model. For rate constants that had relatively high
sensitivities, we tested the robustness of the parameters
by perturbing the values within +/− 30%. Table 7 shows
the results of the perturbation test. In all cases tested,
the level of apoptosis changed slightly, within +/−10%
according to the variation in the chosen parameter, except
for parameters, k1 and k13, demonstrating the overall
robustness of the simulation results with respect to
parameter perturbations.
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